High Ly6D mRNA expression in breast cancer was significantly correlated with poor outcome in five-year distant metastasis free survival (low Ly6D, n=818; high Ly6D, n=790; HR=1.29, p=0.012, n= number of patient, HR=hazard ratio), post progression free survival (low Ly6D, n=231; high Ly6D, n=120; HR=1.57, p=9.0E-04), relapse free survival (low Ly6D, n=1133; high Ly6D, n=2421; HR=1.30, p=2.0E-05) shown by KM plotter and five-year relapse free survival (low Ly6D, n=57; high Ly6D, n=57; HR=1.48, p=0.006) shown by PROGgeneV2 (Table S1, Figure 1A). Here, LY6D is linked to breast carcinoma.